Gilead Sciences, Inc
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; and oNKo-innate Pty. Ltd. The company was founded in 1987 and is headquartered in Foster City, California. Show More...
-
Website http://www.gilead.com
-
Sector Healthcare
-
Industry Drug Manufacturers-General
-
Last Quote 110.08 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD 1.66 1.77 1.64 1.81 7.35 11.91 9.94 3.51 4.17 4.22 3.9 Dividends USD 1.29 1.84 2.08 2.28 2.52 2.57 Payout Ratio % * 7.8 16.7 23.0 182.8 116.0 65.9 Shares Mil 1.747 1.58 1.583 1.695 1.647 1.521 1.358 1.319 1.308 1.277 1.274 Book Value Per Share * USD 3.66 4.06 6.13 7.09 9.05 12.25 12.88 18.99 17.83 16.27 17.59 Free Cash Flow Per Share * USD 1.59 2.02 1.77 1.61 6.01 11.4 12.42 8.91 6.02 6.27 Return on Assets % 27.25 19.41 13.45 14.06 42.34 41.87 24.81 7.27 8.14 8.6 8.1 Financial Leverage (Average) 1.98 2.57 2.28 1.98 2.25 2.8 3.02 3.44 2.98 2.74 2.71 Return on Equity % 47.44 44.49 32.3 29.74 90.32 106.64 72.16 23.53 26.08 24.53 22.55 Return on Invested Capital % 34.41 24.45 17.87 18.56 54.26 54.52 33.57 10.39 12.09 12.76 11.99 Interest Coverage 36.92 18.77 11.01 14.71 37.06 32.48 18.74 13.1 8.24 6.19 5.9 Current Ratio 2.32 5.53 1.44 1.15 3.07 2.5 2.22 2.74 3.38 3.1 3.04 Quick Ratio 1.51 4.71 0.85 0.67 2.56 2.07 1.78 2.52 3.15 2.86 2.78 Debt/Equity 0.5 1.13 0.76 0.35 0.77 1.14 1.39 1.51 1.15 0.98 1.0